ReviewClinical epigenetics2026
Epigenetics-mediated pathological alterations and their diagnostic and therapeutic potential in sepsis-associated acute kidney injury.
Review in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Sepsis-associated acute kidney injury (SA-AKI) is a prevalent and life-threatening condition among critically ill patients. At present, studies on SA-AKI are still in the experimental stage, and comprehensively elucidating the pathogenesis of SA-AKI would effectively promote the development of diagnostic and therapeutic for SA-AKI. Emerging evidence highlights the critical role of cell-specific epigenetic dysregulation in the severity and progression of SA-AKI, particularly in monocytes, macrophages, neutrophils, endothelial cells (ECs), and renal tubular epithelial cells (RTECs). Classical epigenetic modifications, including DNA methylation and histone modifications, serve as pivotal regulators of gene transcription, influencing multiple pathological processes, including inflammatory responses, microcirculatory dysfunction, and metabolic reprogramming during SA-AKI. Therefore, this review aims to provide a comprehensive analysis of the underlying epigenetic mechanisms of SA-AKI progression and explore the potential of epigenetic markers as diagnostic tools and therapeutic targets. Finally, we propose that targeting epigenetic modifications could pave the way for novel diagnostic strategies and precision medicine to improve SA-AKI outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.